- Home
- RCUS vs GBX Comparison
RCUS vs GBX Comparison
Compare RCUS & GBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCUS
- GBX
- Stock Information
- Founded
- RCUS 2015
- GBX 1974
- Country
- RCUS United States
- GBX United States
- Employees
- RCUS N/A
- GBX N/A
- Industry
- RCUS Biotechnology: Pharmaceutical Preparations
- GBX Railroads
- Sector
- RCUS Health Care
- GBX Industrials
- Exchange
- RCUS Nasdaq
- GBX Nasdaq
- Market Cap
- RCUS 1.2B
- GBX 1.5B
- IPO Year
- RCUS 2018
- GBX N/A
- Fundamental
- Price
- RCUS $17.35
- GBX $46.02
- Analyst Decision
- RCUS Buy
- GBX Hold
- Analyst Count
- RCUS 8
- GBX 2
- Target Price
- RCUS $26.50
- GBX $59.50
- AVG Volume (30 Days)
- RCUS 1.2M
- GBX 256.0K
- Earning Date
- RCUS 11-05-2025
- GBX 10-28-2025
- Dividend Yield
- RCUS N/A
- GBX 2.79%
- EPS Growth
- RCUS N/A
- GBX 88.14
- EPS
- RCUS N/A
- GBX 7.10
- Revenue
- RCUS $262,000,000.00
- GBX $3,533,700,000.00
- Revenue This Year
- RCUS N/A
- GBX N/A
- Revenue Next Year
- RCUS N/A
- GBX N/A
- P/E Ratio
- RCUS N/A
- GBX $6.47
- Revenue Growth
- RCUS 6.07
- GBX 0.70
- 52 Week Low
- RCUS $6.50
- GBX $37.77
- 52 Week High
- RCUS $18.98
- GBX $71.06
- Technical
- Relative Strength Index (RSI)
- RCUS 64.78
- GBX 51.44
- Support Level
- RCUS $16.41
- GBX $45.20
- Resistance Level
- RCUS $18.42
- GBX $46.43
- Average True Range (ATR)
- RCUS 1.17
- GBX 1.04
- MACD
- RCUS 0.04
- GBX 0.09
- Stochastic Oscillator
- RCUS 75.30
- GBX 76.23
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
About GBX Greenbrier Companies Inc. (The)
Greenbrier Companies Inc designs, manufactures, and markets railroad freight car equipment in North America and Europe, marine barges in North America and provides wheel services, railcar refurbishment, and parts, leasing and other services to the railroad. Its segments include Manufacturing, Maintenance Services and Leasing & Management Services. The company generates a majority of its revenue from the manufacturing segment. Geographically, it derives a majority of its revenue from the United States.